Allogene Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Allogene Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). De-risked biotech with critical 2026 inflection points in oncology (ALPHA3) and autoimmune (ALLO-329) programs that could reshape CAR T therapeutics if successful. With a cash runway to 2027 and 2026's dual catalysts, ALLO offers a rare combination of safety and upside. However, the company faces significant financial headwinds with.
What is Allogene Therapeutics, Inc.'s industry? Allogene Therapeutics, Inc. (allogene.com) operates in Biopharmaceutical / Cell Therapy (Allogeneic CAR-T). AskCyborg classifies Allogene Therapeutics, Inc. under Biopharmaceutical / Cell Therapy (Allogeneic CAR-T) in its company registry.
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. The company is developing "off-the-shelf" CAR T ce...
Cyborg Score thesis
De-risked biotech with critical 2026 inflection points in oncology (ALPHA3) and autoimmune (ALLO-329) programs that could reshape...
Read the full analyst-debate transcript →Get the Latest Allogene Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAllogene Therapeutics, Inc. Overview
Pro stress-test →Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. The company is developing "off-the-shelf" CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Strategic Profile
Pro stress-test →After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, Allogene has built an off-the-shelf CAR T platform designed to deliver clinical utility, broad patient access, predictable manufacturing, and scalable economics. The company has achieved a burn rate 28% lower than its 2023 peak with runway spanning two pivotal data-readout years, which buys ALLO time to execute without needing dilutive financing.
Competitive Landscape
Pro stress-test →Allogene has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. As a clinical-stage company, Allogene competes with autologous CAR-T leaders (Gilead/Kite, Novartis) and emerging allogeneic competitors, differentiated by its off-the-shelf manufacturing approach and potential for broader scalability.
Industry Context
Allogene Therapeutics, Inc. operates in Biopharmaceutical / Cell Therapy (Allogeneic CAR-T).
Key facts
Founded: 2017 · Headquarters: South San Francisco, California · Revenue: $22K · Market cap: $2.4B